Recruiting Pulmonary Hypertension Studies in Englewood
A Trial of Lu AF82422 in Participants With Multiple System Atrophy (MSA)
The main goal of this trial is to evaluate the efficacy and safety of Lu AF82422 for the treatment of participants with Multiple System Atrophy (MSA)....
A Study to Investigate the Efficacy and Safety of NSI-8226 in Adults With Eosinophilic Esophagitis
Phase 2 study to evaluate the safety, tolerability, PK, immunogenicity, and pharmacodynamics of solrikitug in adult participants with eosinophilic esophagitis....
About Pulmonary Hypertension Clinical Trials in Englewood
Pulmonary hypertension is a type of high blood pressure that affects the arteries in the lungs and the right side of the heart. It can lead to heart failure if untreated. Treatment includes vasodilators, endothelin receptor antagonists, and PDE-5 inhibitors.
There are currently 2 pulmonary hypertension clinical trials recruiting participants in Englewood, NJ. These studies are seeking a combined 517 participants. Research is being sponsored by H. Lundbeck A/S, Uniquity One (UNI). Clinical trial participation is free and participants receive study-related medical care at no cost.
Pulmonary Hypertension Clinical Trials in Englewood — FAQ
Are there pulmonary hypertension clinical trials in Englewood?
Yes, there are 2 pulmonary hypertension clinical trials currently recruiting in Englewood, NJ. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Englewood?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Englewood research site will contact you about next steps.
Are clinical trials in Englewood free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Englewood studies also compensate for your time and travel.
What pulmonary hypertension treatments are being tested?
The 2 active trials in Englewood are testing new therapies including novel drugs, biologics, and treatment approaches for pulmonary hypertension.
Data updated March 2, 2026 from ClinicalTrials.gov